Syros Pharmaceuticals, Inc. (SYRS)
Fuera de horario:
Syros Pharmaceuticals, Inc.
35 CambridgePark Drive
4th Floor
Cambridge, MA 02140
United States
617 744 1340
https://www.syros.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 68
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Richard A. Young Ph.D. | Scientific Founder, Member of Scientific Advisory Board & Director | 108.37k | N/D | 1954 |
| Dr. David A. Roth M.D. | Chief Medical Officer | 679.52k | N/D | 1963 |
| Mr. Conley Chee | CEO, President & Director | N/D | N/D | 1970 |
| Dr. James E. Bradner M.D. | Founder | N/D | N/D | 1972 |
| Dr. Nathanael S. Gray Ph.D. | Scientific Founder & Member of Scientific Advisory Board | N/D | N/D | N/D |
| Mr. Jason Haas | Chief Financial Officer | 457.22k | N/D | 1968 |
| Ms. Karen Hunady M.S. | Director of Corporate Communications & Investor Relations | N/D | N/D | N/D |
| Mr. Gerald E. Quirk Esq., J.D. | Chief Legal Officer & Head of Business Development | 127.07k | N/D | 1968 |
| Ms. Lisa Roberts | Vice President of Human Resources | N/D | N/D | N/D |
| Ms. Kristin Stephens | Chief Development Officer | N/D | N/D | 1973 |
Descripción
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.
Gestión corporativa
La calificación ISS Governance QuickScore de Syros Pharmaceuticals, Inc. a partir del 1 de mayo de 2024 es 8. Las puntuaciones principales son Auditoría: 7; Junta: 7; Derechos del accionista: 8; Compensación: 8.
